MedTrace Logo

Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management

NCT02271893 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2022-10-10

No results posted yet for this study

Summary

The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.

Conditions

  • Chemotherapy-induced Peripheral Neuropathy

Interventions

DRUG

Dextromethorphan

The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.

Sponsors & Collaborators

  • Dr Gisèle PICKERING

    collaborator UNKNOWN

  • Dr Dominique JOLY / Dr Christine VILLATTE

    collaborator UNKNOWN

  • Dr Noémie DELAGE / Dr Fabienne MARCAILLOU / Dr Pascale PICARD

    collaborator UNKNOWN

  • Pr Claude DUBRAY

    collaborator UNKNOWN

  • University Hospital, Clermont-Ferrand

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-25
Primary Completion
2017-10-26
Completion
2022-04-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02271893 on ClinicalTrials.gov